Kenvue India presents report on ‘The Hydration Gap for Non-Diarrheal Illnesses’

The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery

Granules India FDA approval for ADHD treatment

Bayer announces positive topline resukts for Aflibercept 8 mg in phase III study

Demonstrates vision gains with extended treatment intervals in retinal vein occlusion

Rusan Pharma achieves GMP approvals from TGA (Australia) and ANVISA (Brazil) for its manufacturing facility in Kandla SEZ

The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market

Jitendra Singh releases landmark RSSDI study ' Indian Prevention of Diabetes Study (IPDS) on Yoga and Diabetes Prevention'

A 40 minute daily Yoga routine, incorporating select asanas and pranayama, along with standard lifestyle interventions, can reduce the risk of developing diabetes by approximately 40%

Aster DM Healthcare launches precision oncology, offering data-driven, personalized cancer care

Harnessing advanced data analysis for early detection, prevention and better outcomes

Lupin acquires 3 Trademarks from Boehringer Ingelheim for diabetes portfolio

The trademark rights for these brands will be transferred to Lupin by March next year.

Pfizer announces Phase 3 PATINA study in patients with HR+, HER2+ metastatic breast cancer

IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy

Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase 3 trial

First and only PARP inhibitor to improve overall survival in early breast cancer

Arvinas and Pfizer presents phase 1b data from the TACTIVE-U sub-study of Vepdegestrant in combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium

Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate